Lithuania's Sanitas reports flat turnover

10 July 2001

Lithuania's largest pharmaceuticals producer, Sanitas, has recordedsales of 12.2 million litas ($3.1 million) in the first half of 2001, around the same level as its turnover in the corresponding period last year, according to the LETA news agency. However, it was noted that the group's sales in June soared 28.3% year-on-year to 2.66 million litas.

In the first five months of this year, Sanitas recorded operating profits of 261,000 litas, after overcoming a first-quarter loss, while for 2001 as a whole, the company is forecasting net profits of 1.4 million litas on turnover worth 34.8 million litas. Both figures are substantially higher than those posted last year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight